Mengis Capital Management Inc. Decreases Holdings in Bristol Myers Squibb Company $BMY

Mengis Capital Management Inc. lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 16.5% during the third quarter, HoldingsChannel.com reports. The fund owned 47,434 shares of the biopharmaceutical company’s stock after selling 9,349 shares during the quarter. Mengis Capital Management Inc.’s holdings in Bristol Myers Squibb were worth $2,139,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of BMY. Vanguard Group Inc. increased its position in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after buying an additional 1,058,803 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC increased its holdings in Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares in the last quarter. Norges Bank acquired a new position in Bristol Myers Squibb during the second quarter worth about $1,554,154,000. Finally, Ameriprise Financial Inc. grew its position in shares of Bristol Myers Squibb by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 1.8%

BMY opened at $62.32 on Thursday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The business has a 50-day moving average of $57.42 and a two-hundred day moving average of $50.84. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock has a market capitalization of $126.91 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the previous year, the company earned $1.67 earnings per share. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BMY. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Morgan Stanley reiterated an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Citigroup boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $60.71.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.